Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb;17(2):73-74.
doi: 10.1038/s41571-019-0317-y.

Frontline immunotherapy for NSCLC - the tale of the tail

Anne C Chiang  1 , Roy S Herbst  2
Affiliations
Comment

Frontline immunotherapy for NSCLC - the tale of the tail

Anne C Chiang et al. Nat Rev Clin Oncol. 2020 Feb.
No abstract available

PubMed Disclaimer

Comment on

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
    Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Hellmann MD, et al. N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562796 Clinical Trial.

References

    1. Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 346, 1823–1833 (2016). - DOI
    1. Mok, T. S. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. Lancet. 393, 1819–1830 (2019). - DOI
    1. Spiegel, D. R. et al. LBA78 — IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo versus platinum-based chemotherapy (chemo) as first-line (1 L) treatment (tx) in PD-L1-selected NSCLC. Ann. Oncol. 30 (suppl. 5), v851–v934 (2019).
    1. Reck, M. et al. OA14.01 KEYNOTE-024 3-year survival update: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer. J. Thorac. Oncol. 14 (Suppl.), S243 (2019). - DOI
    1. Nadal, E. et al. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol. Immunother. 68, 341–352 (2019). - DOI

LinkOut - more resources